In search of a molecular diagnosis for a child with bilateral vestibular schwannomas, a family undergoes a diagnostic odyssey ...

The company said it will use the funds raised from sales of convertible notes to fund its oncology business, including intismeran autogene.

BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA vaccine ...

The hospital, which has been making investments into precision medicine, inked a multi-phase deal to integrate PGx into clinical workflows.

Regulators approved the FGFR1/2/3 inhibitor based on data showing a 42.5 percent objective response rate and 16.6 months of median overall survival.

Sangrail Biologics is already discussing with the FDA a regulatory path for the gene therapy that Abeona Therapeutics dropped ...

NEW YORK –Ideaya Biosciences and Genentech on Wednesday said they will study Ideaya's PRMT5 inhibitor IDE892 with Genentech's KRAS G12D inhibitor GDC-7035 in patients with pancreatic cancer. The trial ...

University of Toronto researchers are betting yes, pointing to tRNA's ease of administration and efficacy advantages over ...

NEW YORK – Adaptin Bio is launching a Phase I trial of a T-cell engager in patients with malignant brain tumors harboring EGFR variant III mutations. The 15-patient study — the company's first — will ...

For patients with microsatellite instability of mismatch repair deficiency, the final decision cements access to the drug, which was previously offered provisionally.

NEW YORK – An analysis of Medicare claims data over seven years found that uptake of next-generation sequencing in cancer was slower than expected after Medicare began covering testing. The research, ...

The firm is testing the next dose level of RV-01 in a Phase I/IIa study after clearance from a safety and monitoring committee.